Overview

Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, dose escalation study.
Phase:
Phase 1
Details
Lead Sponsor:
Tragara Pharmaceuticals, Inc.
Treatments:
Citric Acid